Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dronabinol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| All Enrolled Participants | EXPERIMENTAL | Each participant receives all treatments (of placebo, dronabinol 10 mg and dronabinol 30 mg) in a 5-way crossover design. At each treatment visit, participants receive a single dose, contained in two syringes of oral solution and three capsules. When dronabinol is in syringes, placebo is in capsules, and when dronabinol is in capsules, placebo is in syringes. When assigned to take placebo only, placebo is in both the syringes and the capsules. |
| Name | Type | Description |
|---|---|---|
| Dronabinol 10 mg | DRUG | Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes. |
| Dronabinol 30 mg | DRUG | Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes. |
| Placebo | DRUG | Matching placebo provided in capsules or as an oral solution in syringes. |
Inclusion Criteria: * Healthy adult protocol-defined recreational cannabinoid user * Meets protocol-specified criteria for qualification and contraception * Able to speak, read and understand English well enough to understand the nature of the study, provide written informed consent, and to allow c...
Dronabinol is being studied for use in drug abuse and medication-related conditions. It is an investigational small molecule currently in clinical development, with a completed Phase 1 trial evaluating its abuse potential in recreational cannabinoid users.
Dronabinol is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker YCBD. The company is conducting clinical research on the drug for drug abuse and medication-related indications.
Dronabinol is in Phase 1 of clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effects.
Dronabinol has one completed clinical trial, registered under NCT02094599, titled "A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users." The study was a Phase 1, double-blind, uncontrolled trial conducted in Canada with 43 participants.
Dronabinol is a distinct drug being developed by cbdMD, Inc. It is a small molecule and is being studied for its effects in drug abuse and medication-related conditions, based on its clinical trial in recreational cannabinoid users.